GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Alligator Bioscience AB (LTS:0RK9) » Definitions » Cyclically Adjusted PS Ratio

Alligator Bioscience AB (LTS:0RK9) Cyclically Adjusted PS Ratio : (As of Jun. 03, 2025)


View and export this data going back to 2016. Start your Free Trial

What is Alligator Bioscience AB Cyclically Adjusted PS Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


Alligator Bioscience AB Cyclically Adjusted PS Ratio Historical Data

The historical data trend for Alligator Bioscience AB's Cyclically Adjusted PS Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Alligator Bioscience AB Cyclically Adjusted PS Ratio Chart

Alligator Bioscience AB Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Cyclically Adjusted PS Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Alligator Bioscience AB Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Cyclically Adjusted PS Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Alligator Bioscience AB's Cyclically Adjusted PS Ratio

For the Biotechnology subindustry, Alligator Bioscience AB's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Alligator Bioscience AB's Cyclically Adjusted PS Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Alligator Bioscience AB's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Alligator Bioscience AB's Cyclically Adjusted PS Ratio falls into.


;
;

Alligator Bioscience AB Cyclically Adjusted PS Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PS Ratio takes the Revenue per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/S calculation. Because it considers this 10-year average, it's often referred to as the CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio.

Alligator Bioscience AB's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2025 is calculated as:

For example, Alligator Bioscience AB's adjusted Revenue per Share data for the three months ended in Mar. 2025 was:

Adj_RevenuePerShare=Revenue per Share/CPI of Mar. 2025 (Change)*Current CPI (Mar. 2025)
=0/132.8245*132.8245
=0.000

Current CPI (Mar. 2025) = 132.8245.

Alligator Bioscience AB Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201412 0.000 100.225 0.000
201509 186.036 100.228 246.540
201512 0.329 100.276 0.436
201603 27.884 100.751 36.761
201606 2.435 101.019 3.202
201609 2.997 101.138 3.936
201612 4.607 102.022 5.998
201703 1.602 102.022 2.086
201706 0.809 102.752 1.046
201709 1.116 103.279 1.435
201712 32.344 103.793 41.391
201803 0.489 103.962 0.625
201806 0.247 104.875 0.313
201809 0.124 105.679 0.156
201812 16.137 105.912 20.238
201903 0.025 105.886 0.031
201906 0.019 106.742 0.024
201909 2.704 107.214 3.350
201912 0.000 107.766 0.000
202003 0.000 106.563 0.000
202006 2.861 107.498 3.535
202009 0.000 107.635 0.000
202012 0.000 108.296 0.000
202103 0.407 108.360 0.499
202106 2.365 108.928 2.884
202109 1.974 110.338 2.376
202112 2.646 112.486 3.124
202203 1.244 114.825 1.439
202206 1.982 118.384 2.224
202209 1.958 122.296 2.127
202212 7.690 126.365 8.083
202303 3.677 127.042 3.844
202306 4.360 129.407 4.475
202309 2.595 130.224 2.647
202312 1.508 131.912 1.518
202403 0.897 132.205 0.901
202406 0.864 132.716 0.865
202409 0.160 132.304 0.161
202412 4.660 132.987 4.654
202503 0.000 132.825 0.000

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Alligator Bioscience AB  (LTS:0RK9) Cyclically Adjusted PS Ratio Explanation

Compared with the regular PS Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PS Ratio smoothed out the fluctuations of revenue during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PS Ratio should give similar results to regular PS Ratio.


Alligator Bioscience AB Cyclically Adjusted PS Ratio Related Terms

Thank you for viewing the detailed overview of Alligator Bioscience AB's Cyclically Adjusted PS Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Alligator Bioscience AB Business Description

Traded in Other Exchanges
Address
Medicon Village, Scheeletorget 1, Lund, SWE, 223 81
Alligator Bioscience AB is a clinical-stage biotechnology company developing tumor-directed immuno-oncology antibody drugs focused on the CD40 receptor. Its drug candidate mitazalimab, is currently in preparation for Phase 3 development, and has previously presented unprecedented survival data at 18-months follow up in first-line metastatic pancreatic cancer patients in the Phase 2 trial OPTIMIZE-1.

Alligator Bioscience AB Headlines

No Headlines